Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in Cataract Surgery
NCT04668456Phase 3
Key facts
- Status
- Unknown
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Countries
- 1
- Sponsor
- Menoufia University
- Modality
- Small Molecules
- Drugs
- dexmedetomidine
- Conditions
- cataract
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in cataract (3 arms), sponsored by Menoufia University. Primary endpoint: Duration of sensory block at 24 hours. Status: unknown.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Control Group
Subtenon LA (bupivacaine + lidocaine + saline) + IV saline
Subtenon Dexmedetomidine
Subtenon LA (bupivacaine + lidocaine + dexmedetomidine) + IV saline
IV Dexmedetomidine
Subtenon LA (bupivacaine + lidocaine + saline) + IV dexmedetomidine
03
Who it enrols
Adult patients (18-70 years) scheduled for elective phacoemulsification cataract surgery, excluding those with coagulation abnormalities, impaired mental status, uncontrolled glaucoma, or recent eye surgery.
04
Endpoints
Primary
Duration of sensory block
Secondary
Duration of motor block
Beyond the preview
Go deeper on NCT04668456.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668456.